PL84267B1 - - Google Patents
Download PDFInfo
- Publication number
- PL84267B1 PL84267B1 PL1971174909A PL17490971A PL84267B1 PL 84267 B1 PL84267 B1 PL 84267B1 PL 1971174909 A PL1971174909 A PL 1971174909A PL 17490971 A PL17490971 A PL 17490971A PL 84267 B1 PL84267 B1 PL 84267B1
- Authority
- PL
- Poland
- Prior art keywords
- group
- carbon atoms
- ch2oh
- hydrogen
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- -1 3,4-methylenedioxy group Chemical group 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002908 adrenolytic effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- YIUIVFFUEVPRIU-UHFFFAOYSA-N 8-chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21 YIUIVFFUEVPRIU-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- GPKDFTKUEQUSCC-UHFFFAOYSA-N Cl.C(#N)C1=C(OC(C(CC(CO)(C)C)O)N)C=CC=C1 Chemical compound Cl.C(#N)C1=C(OC(C(CC(CO)(C)C)O)N)C=CC=C1 GPKDFTKUEQUSCC-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940075065 polyvinyl acetate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical group CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Description
Przedmiotem wynalazku jest sposób wytwarzania nowych 1-fenoksy-2-hydroksy-3-hydroksyalkiloami- nopropanów w postaci racematów lub optycznych antypodów, ich estrów i soli addycyjnych z kwa¬ sami. 5 Nowym zwiazkom odpowiada wzór ogólny 1, w którym Rt oznacza grupe o wzorze (CH2)X—CN, (CH2)x^NH, lub (OH2)X +1^OH (prey czym x ozna¬ cza liczbe calkowita 0—3), grupe o wzorze —COOR5 (pffzy czym R3 oznacza wodór lub grupe alkilowa io o 1—4 atomach wegla), grupe alkenylowa, alkenylo- ksylowa, alkinylowa lub alkinyioksylowa o 2—5 ato¬ mach wegla, R2 oznacza wodór, chlorowiec, grupe alkilowa lub aiiktotosylowa o 1—4 atomach wegla, grupe alkenylowa ó 2—5 atomach wegla, grupe nitry- 15 Iowa lub nitrowa lub razem z Rt oznaczaja grupe 3,4-metylenodwuoksylowa, R3 oznacza wodór, chlo¬ rowiec lub grupe alkilowa wzglednie alkoksylowa o 1—4 atomach wegla i R4 oznacza prosta lub roz¬ galeziona grupe hydroksalkilowa o 3—6 atomach 2o Wegla.Wedlug wynalazku nowe zwiazki wytwarza sie przez hydrolize oksazolidynonu o wzorze ogólnym 2, W którym Ri—R4 maja wyzej podane znaczenie, np. za pomoca mocnych alkalii w wodnym lub wodno- 25 alkoholowym srodowisku. Stosowane jako produkty wyjsciowe oksazolidynony o wzorze 2, wytwarza sie, np. z odpowiednich epoksydów, które wprowadza sie w reakcje z otrzymanym z eteru etylowego Kwa¬ su chloromrówkowego i hydroksyalkioaminy, ureta- 30 2 nem o wzorze 3, w którym R4 ma wyzej podane zna¬ czenie.Otrzymywane sposobem wedlug wynalazku zwiaz¬ ki posiadaja asymetryczny atom wegla w grupie CHOH i moga przeto wystepowac w postaci racema¬ tów oraz optycznie czynnych antypodów. Te ostatnie mozna uzyskac przez rozdzielenie racematu za po¬ moca zwykle uzywanych kwasów pomocniczych, ta-^ kich jak kwas dwubenzoilo-(wzglednie dwu-p-tolu- ilo-)D-wiinowy luk kwas D^tofPoamllkiamfoiiewS^fliirffo- nowy oraz przez stosowanie optycanie czynnych zwiazków wyflsciowyicn.Otrzymywane sposobem wedlug wynalazku 1-fe- noksy-2-hydroksy^3-hydroksyalkiloaminoproicany o wzorze ogólnym 1 mozna przeprowadzac W znan^ sposób w ich fizjologicznie dopuszczalne sole addy* cyjne z takimi kwasami1, jak np. kwas solny, b#o~ mowodorowy, siarkowy, metanoeuilonówy,' maleiDtó* wy, octowy, szczawiowy, mlekowy, winowy lub 8- -chloroteofilina. Równiez przeprowadzenie tych zwiazków w ich estry zachodzi w znany sposób np. przez reakcje z halogenkami lub bezwodnikami acy- lowymi. Najuzyteczniejszymi estrami sa np. 2-oeta- ny wzglednie 2~propioniany.Zwiazki o wzorze ogólnym 1 wzglednie ich fizjo^ logicznie dopuszczalne sole addycyjne z kwasami wykasuja w badianiacn na swinkach morstoLch waav tosciowe wlasciwosci terapeutyczne, zwlaszcza dzia^ lanie ^-adrenolityczne i mozna je przeto stosowac do leczenia lub profilaktyki schorzen naczyn wien- 8426784 267 cowych serca i arytmii serca, w szczególnosci tycho- cardii w medycynie. Równiez dzialanie obnizajace cisnienie krwi jest pod wzgledem terapeutycznym interesujace. Nowe zwiazki, w porównaniu ze zna¬ nymi zwiazkami blokujacymi /Preceptory np. z 1- ^(1-njafltylcfey)-E-hydiro^ nem (propanicdoilem), sa 'zoaczinie mndej toiksyclzine.Szczególnie wartosciowymi okazaly sie zwiazki o wzorze 1, w którym R4 oznacza grupe hydroksy- alkilowa, zwlaszcza grupe l,l-dwumetylo-2-hydro- ksyetylowa. Dalej, w przypadku gdy R2 i R3 ozna¬ czaja zwlaszcza wodór, a równiez grupe alkilowa i Ri oznacza zwlaszcza nienasycona grupe, taka jak grupa etynylowa, nitrylowa, allilowa lub alliloksy- lowa (w szczególnosci w polozeniu 2 lancucha pro- panolowego) lub takze grupe hydroksymetylowa, to takie zwiazki odznaczaja sie szczególnie korzystnym zakresem dzialania. Specjalnie korzystnymi pod wzgledem temapeutycznyim sa l-(2-etyinylofeno!ksy)-2- -hydroksy-3-(ljl-dwumetylo-2-,hydroksyetylo)-ami- nopropan i l-(2-cyjanofenoksy)-2-hydroksy-3-)l,l- -dwumetylo-2-hydroksyetylo)-aminopropan wzgled¬ nie fizjoloigiicziniie dopuszczalne sole addycyjne z kwasami i estry tych zwiazków. Bardzo dobrze dzialaja równiez zwiazki, w których grupa fenyIowa jest podstawiona grupa nitrylowa w polozeniu 2 i równoczesnie nizsza grupa alkilowa, zwlaszcza gru¬ pa metylowa w polozeniu 5 np. l-(2-cyjano-5-mety- lofenoksy)-2-hydroksy-3-(l,l-dwumetylo-2-hydro- ksyetylo)-aminopropan wzglednie jego fizjologicznie diopusizczaitoie sole addycyjne z kwasaimi i estry.Dawka jednostkowa zwiazków otrzymywanych spo¬ sobem wedlug wynalazku wynosi 1—300 mg, zwlasz¬ cza 5—100 mg (doustnie) wzglednie 1—20 mg (poza- jelitowo).Nowe zwiazki mozna przeprowadzic w zwykle sto¬ sowane galenowe formy uzytkowe, takie jak tabletki, drazetki, roztwory, emulsje, proszki, kapsulki lub preparaty o przedluzonym dzialaniu, przy czym wy¬ twarzanie ich zachodzi z zastosowaniem znanych farmaceutycznych srodków pomocniczych, w znany sposób. Tabletki np. mozna wytwarzac przez zmie¬ szanie substancji czynnej ze znanymi srodkami po¬ mocniczymi, np. obojetnymi rozcienczalnikami, jak weglan lub fosforan wapnia lub cukier mlekowy, srodkami rozkruszajacymi, jak skrobia kukurydziana lub kwas alginowy, srodkami wiazacymi, jak skro¬ bia lub zelatyna i/lub srodkami wywolujacymi efekt przedluzonego dzialania, takimi jak karboksypolime- tylen, karboksymetyloceluloza, ftalan acetylocelulozy lub polioctan winylu. Tabletki moga skladac sie rów¬ niez z kilku warstw. Drazetki otrzymuje sie przez powlekanie rdzeni, wytworzonych analogicznie jak tabletki^ zwykle stosowanymi powlokami drazeitiko- wymi np. z kolidonu lub szelaku, gumy arabskiej, 36 40 50 55 talku, dwutlenku tytanu lub cukru. Dla osiagniecia przedluzonego dzialania lub unikniecia niezgodnosci mozna wytwarzac rdzenie Wielowarstwowe, przy czym stosuje sie wsipoanniane przy tabletJkacih srodki pomocnicze. Eliksiry zawierajace substancje czynna lub polaczenie substancji czynnych moga zawierac dodatek srodka slodzacego, takiego jak sacharyna, cyklaminian, gliceryna lub cukier, oraz srodki po¬ lepszajace smak np. srodki aromatyzujace np. wani¬ lina lub ekstrakt pomaranczowy. Ponadto moga one zawierac pomocnicze srodki zawieszajace lub zagesz¬ czajace, jak sól sodowa karboksymetylocelulozy, sro¬ dek zwilzajacy, np. produkt kondensacji alkoholi tluszczowych z tlenkiem etylenu lub srodki konser¬ wujace, jak p-hydroksybenzoesan. Roztwory injek- cyjne wytwarza sie w znany sposób, np. z dodatkiem srodka konserwujacego, jak p-hydroksybenzoesan lub stabilizatora, jak komplekson. Roztworem takim napelnia sie fiolki dnjekcyjne i aimpoilki. Kapsulki, zawierajace substancje czynna lub kombinacje sub¬ stancji czynnych, wytwarza sie, np. przez zmieszanie substancji czynnej z obojetnym nosnikiem, jak cu¬ kier mlekowy lub sorbit i mieszanina ta napelnia sie kapsulki zelatynowe i zamyka. Czopki, np. wytwarza sie przez zmieszanie substancji czynnej lub polacze¬ nia substancji czynnych ze zwykle stosowanymi no¬ snikami, jak tluszcze obojetne lub glikol polietyle¬ nowy wzglednie jego pochodne.Zwiazki otrzymywane sposobem wedlug wynalaz¬ ku mozna laczyc z innymi farmakodynamicznie czyn¬ nymi substancjami, takimi jak srodki rozszerzajace naczynia wiencowe, srodki sympatykomimetyczne, glikozydy nasercowe lub srodki uspokajajace. Naste¬ pujacy przyklad wyjasnia blizej wynalazek nie ogra¬ niczajac jego zakresu.Przyklad. Chlorowodorek 1-(2-cyjanofenoksy)- -2-hydroksy-3-(1,1 -dwumetylo-2-hydroksyetylo)- -aminopropanu. 5,8 g (0,02 mola) 3-(l,l-dwumetylo- -2-hydroksyetylo) -5-(2-cyjanofenoksymetylo) -oksa- zolidynonu-2- w mieszaninie z 12 ml wody i 30 ml etanolu, po dodaniu 5,6 g (0,1 mola) KOH ogrzewa sie do wrzenia przez 2 godziny pod chlodnica zwrot¬ na. Nastepnie oddestylowuje sie rozpuszczalnik, po¬ zostalosc ekstrahuje sie woda i zakwasza HC1. Kwa¬ sny wodny roztwór wytraca sie z chloroformem i na¬ stepnie alkalizuje za pomoca NaOH. Wytracony osad rozpuszcza sie w chloroformie, faze organiczna prze¬ mywa sie woda i suszy nad siarczanem sodowym. Po oddestylowaniu rozpuszczalnika pozostalosc rozpusz¬ cza sie w malej ilosci octanu etylenu i dodaje eteru naftowego (temperatura wrzenia 40°C). Krystalizuje bezbarwna zasada, która jest chromatograficznie czy¬ sta/Temperatura topnienia: 100—102°C.Analogicznie wytwarza sie nastepujace zwiazki o wzorze 1: ¦ Ri | i 2—CN 2—CN 2—CN 2—O—CHt—CH=*CH2 R, 2 H H - H R3 3 H H H H R4 4 —C(CH3)2^CH2OH —CH(C2H5)—CH2OH —C(CH3)2—CH2OH —C(CH3)2^CH2OH Temperatura topnienia °C 132—134 (chlorowodorek) 106—108 (chlorowodorek) 193—196 (chlorowodorek) 76—79 (chlorowodorek) |84267 1 2—C=CH 2—O—CH2—CH=CH2 2—O—CH2—CH=CH2 2—CH2—C=CH 2—CH2—C=CH 2—C=CH 2—CN 2—CN 2—CH2—C=CH 2—CH2—CH=CH2 2—CN 4—COOH 3—NH2 4—NH2 2-OCH, 3,4—O^CH2—p— 4—COOH 3—NH2 4—NH2 3,4—O— 2—NH2 2—NH2 2-OCHj 2—COOCH8 2_COOCH8 2—CHeOH 2—CH2OH 2—CH2OH 2—CN 2 H H H H H H H -CH8 H H 4-^01 H H H 4—CN H H H H H 4—CN H H H H H 4—Cl 3 H H H H H H H H H H H H H H H H H H H H H H H H H H H H H 1 4 —C(CH3)2—CH2OH —CH2—CHOH—CHS —CH(CHS)—CH2OH —C(CH8)2—CH2OH —CH(CH3)—CH2OH —CH(CH3)—CH2OH —CH2—CHOH—CH8 —CH2—CHOH—CH8 —CH(C2H5)—CH2OH —C(CH3)2—CH2OH —C(CH8)2—CH2OH —CH(CH5)—CH2OH —CH(CH,)—CH2OH —CH(CH8)—CH2OH —CH(CH3)—CH2OH —C(CH3)2—CH2OH —C(CH3)2—CH2OH —C(CH8)2—CH2OH —C(CH3)2—CH2OH —CH —C(CH8)2—CHjOH —CH(CH3)—CH2OH —C(CH3)2—CH2OH —CH(CH8)—CH2OH —C(CH8)2—CH2OH —C(CH8)2OH —CH(CH8)—CH2OH —C(CH3)2—CH2OH —CH(CH3)—CH2OH 139—141 (chlorowodorek) 82—85 (chlorowodorek) 105—106 63-^66 (Chlorowodorek) 81—84 89—91 (chlorowodorek) 112—116 (chlorowodorek) 143—147 (chlorowodorek) 78—81 63—64 102—103 168—169 (chlorowodorek) 142—143 196 (chlorowodorek) 147 (chlorowodorek) 168 (szczawian) 168 (chlorowodorek) 123—124 93 110 205—207 (dwuchlorowodorek) 196—198 (dwuchlorowodorek) 128—129 (chlorowoKlorek) 81 96 olej olej olej 113—114 | PL PL PL PL
Claims (2)
1. Zastrzezenie patentowe Sposób wytwarzania nowych l-fenoksy-2-hydro- ksy-3-hydroksyalkiloaminopropanów o wzorze ogól¬ nym 1, w którym Rj oznacza grupe o wzorze (CH2)x-CN, (CH2)x—NH2 lub (CH2)x + 1. -OH, przy czym x oznacza liczbe calkowita 0—3, grupe o wzo¬ rze —COOR5, przy czym R5 oznacza wodór lub giru^ pe alkilowa o 1—4 atomach wegla, grupe alkenylowa, alkinylowa, alkenyloksylowa o 2—5 atomach wegla; R2 oznacza wodór, chlorowiec, grupe alkilowa lub alkoksylowa o 1—4 atomach wegla, grupe alkenylo¬ wa o 2—5 atomach wegla, grupe nitrylowa lub ni- 35 40 trowa lub razem z Rt oznaczaja grupe 3,4-metyleno- dwuoksylowa, R, oznacza wodór, chlorowiec lub gru¬ pe alkilowa lub alkoksylowa o 1—4 atomach we¬ gla, R4 oznacza prosta lub rozgaleziona grupe hydro- ksyalkilowa o 3—6 atomach wegla w postaci race- matów i optycznie czynnych antypodów, znamienny tym, ze oksazolidynon o wzorze ogólnym 2, w któ¬ rym Rj—R4 maja wyzej podane znaczenie, hydroli- zuje sie i otrzymany racemat ewentualnie rozszcze¬ pia sie na optyczne antypody i/lub otrzymany zwia¬ zek o wzorze 1 przeprowadza w sól addycyjna z kwa¬ sem lub w ester,84 267 0CH
2. -CH0H-CH2-NH-RA Wzór 1 R,-HN-C-OC9Hc A II 2 5 O Wzór PZG Bydg., zam. 1643/76. nakl. 110 '-20 Cena 10 zl PL PL PL PL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19702048838 DE2048838A1 (de) | 1970-10-05 | 1970-10-05 | Neue 1 Phenoxy 2 hydroxy 3 hydroxyal kylaminopropane und Verfahren zu ihrer Her stellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL84267B1 true PL84267B1 (pl) | 1976-03-31 |
Family
ID=5784228
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1971150902A PL82037B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174909A PL84267B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174908A PL84223B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174910A PL84396B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174903A PL84212B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174906A PL84225B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174911A PL84227B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174912A PL84276B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174905A PL84226B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174907A PL84224B1 (pl) | 1970-10-05 | 1971-10-04 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1971150902A PL82037B1 (pl) | 1970-10-05 | 1971-10-04 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1971174908A PL84223B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174910A PL84396B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174903A PL84212B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174906A PL84225B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174911A PL84227B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174912A PL84276B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174905A PL84226B1 (pl) | 1970-10-05 | 1971-10-04 | |
| PL1971174907A PL84224B1 (pl) | 1970-10-05 | 1971-10-04 |
Country Status (26)
| Country | Link |
|---|---|
| JP (1) | JPS5710097B1 (pl) |
| AT (10) | AT318570B (pl) |
| AU (1) | AU469119B2 (pl) |
| BE (1) | BE773472A (pl) |
| BG (8) | BG18858A3 (pl) |
| CA (1) | CA1008866A (pl) |
| CH (11) | CH583687A5 (pl) |
| CS (2) | CS172932B2 (pl) |
| DE (1) | DE2048838A1 (pl) |
| DK (1) | DK130958B (pl) |
| ES (8) | ES395671A1 (pl) |
| FI (1) | FI55491C (pl) |
| FR (1) | FR2110230B1 (pl) |
| GB (1) | GB1364280A (pl) |
| HU (1) | HU163226B (pl) |
| IE (1) | IE35693B1 (pl) |
| IL (1) | IL37830A (pl) |
| NL (1) | NL174249C (pl) |
| NO (1) | NO132835C (pl) |
| PH (1) | PH9959A (pl) |
| PL (10) | PL82037B1 (pl) |
| RO (8) | RO62267A (pl) |
| SE (1) | SE383631B (pl) |
| SU (2) | SU419024A3 (pl) |
| YU (2) | YU35576B (pl) |
| ZA (1) | ZA716643B (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4055658A (en) * | 1976-05-17 | 1977-10-25 | Mead Johnson & Company | Cyanomethylphenethanolamines |
| US4454154A (en) * | 1981-06-23 | 1984-06-12 | American Hospital Supply Corporation | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents |
| DE3248835A1 (de) * | 1981-06-23 | 1983-06-30 | American Hospital Supply Corp | Zusammensetzungen fuer die behandlung von glaukom |
| US4652584A (en) * | 1984-07-13 | 1987-03-24 | Mcneilab, Inc. | Acetylenic phenoxypropanol derivatives and pharmaceutical compositions for the treatment of hypertension |
| DE4422707A1 (de) | 1994-06-29 | 1996-01-04 | Hoechst Ag | Verfahren zum Färben aminierter Cellulose-/Polyester-Mischgewebe mit faserreaktiven Dispersionsfarbstoffen |
| JP4934287B2 (ja) * | 2005-04-05 | 2012-05-16 | 花王株式会社 | 美白剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD45360A (pl) * | ||||
| CA945172A (en) * | 1969-02-21 | 1974-04-09 | Imperial Chemical Industries Limited | Alkanolamine derivatives |
-
1970
- 1970-10-05 DE DE19702048838 patent/DE2048838A1/de not_active Withdrawn
-
1971
- 1971-04-10 SE SE7112536*A patent/SE383631B/xx unknown
- 1971-09-30 SU SU1700834A patent/SU419024A3/ru active
- 1971-10-01 CH CH424275A patent/CH583687A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424675A patent/CH564516A5/xx not_active IP Right Cessation
- 1971-10-01 IL IL37830A patent/IL37830A/xx unknown
- 1971-10-01 CH CH424575A patent/CH563342A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424075A patent/CH583686A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424175A patent/CH584185A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH1430971A patent/CH564507A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH424375A patent/CH563341A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH423875A patent/CH587223A5/xx not_active IP Right Cessation
- 1971-10-01 CH CH423975A patent/CH583685A5/xx not_active IP Right Cessation
- 1971-10-04 PL PL1971150902A patent/PL82037B1/pl unknown
- 1971-10-04 NO NO3632/71A patent/NO132835C/no unknown
- 1971-10-04 ZA ZA716643A patent/ZA716643B/xx unknown
- 1971-10-04 FI FI2769/71A patent/FI55491C/fi active
- 1971-10-04 BG BG020288A patent/BG18858A3/xx unknown
- 1971-10-04 PL PL1971174909A patent/PL84267B1/pl unknown
- 1971-10-04 PL PL1971174908A patent/PL84223B1/pl unknown
- 1971-10-04 JP JP7778571A patent/JPS5710097B1/ja active Pending
- 1971-10-04 NL NLAANVRAGE7113581,A patent/NL174249C/xx not_active IP Right Cessation
- 1971-10-04 PL PL1971174910A patent/PL84396B1/pl unknown
- 1971-10-04 PL PL1971174903A patent/PL84212B1/pl unknown
- 1971-10-04 PL PL1971174906A patent/PL84225B1/pl unknown
- 1971-10-04 PL PL1971174911A patent/PL84227B1/pl unknown
- 1971-10-04 PL PL1971174912A patent/PL84276B1/pl unknown
- 1971-10-04 CA CA124,290A patent/CA1008866A/en not_active Expired
- 1971-10-04 BG BG20289A patent/BG19134A3/xx unknown
- 1971-10-04 BG BG020290A patent/BG19793A3/xx unknown
- 1971-10-04 PH PH12895A patent/PH9959A/en unknown
- 1971-10-04 PL PL1971174905A patent/PL84226B1/pl unknown
- 1971-10-04 GB GB4610371A patent/GB1364280A/en not_active Expired
- 1971-10-04 DK DK481671AA patent/DK130958B/da not_active IP Right Cessation
- 1971-10-04 ES ES395671A patent/ES395671A1/es not_active Expired
- 1971-10-04 YU YU2505/71A patent/YU35576B/xx unknown
- 1971-10-04 BG BG020291A patent/BG18859A3/xx unknown
- 1971-10-04 BG BG018670A patent/BG20338A3/xx unknown
- 1971-10-04 BG BG020285A patent/BG19133A3/xx unknown
- 1971-10-04 BG BG020286A patent/BG18857A3/xx unknown
- 1971-10-04 PL PL1971174907A patent/PL84224B1/pl unknown
- 1971-10-04 BG BG020287A patent/BG20100A3/xx unknown
- 1971-10-04 BE BE773472A patent/BE773472A/xx not_active IP Right Cessation
- 1971-10-05 CS CS7034A patent/CS172932B2/cs unknown
- 1971-10-05 RO RO7100073337A patent/RO62267A/ro unknown
- 1971-10-05 AT AT735373A patent/AT318570B/de not_active IP Right Cessation
- 1971-10-05 AT AT735173A patent/AT318568B/de not_active IP Right Cessation
- 1971-10-05 FR FR7135823A patent/FR2110230B1/fr not_active Expired
- 1971-10-05 AT AT734773A patent/AT318564B/de not_active IP Right Cessation
- 1971-10-05 AU AU34182/71A patent/AU469119B2/en not_active Expired
- 1971-10-05 AT AT734973A patent/AT318566B/de not_active IP Right Cessation
- 1971-10-05 RO RO7100073338A patent/RO62358A/ro unknown
- 1971-10-05 AT AT735273A patent/AT318569B/de not_active IP Right Cessation
- 1971-10-05 RO RO7100073339A patent/RO62359A/ro unknown
- 1971-10-05 RO RO7100073333A patent/RO62355A/ro unknown
- 1971-10-05 IE IE1246/71A patent/IE35693B1/xx unknown
- 1971-10-05 AT AT735073A patent/AT318567B/de not_active IP Right Cessation
- 1971-10-05 RO RO73336A patent/RO62313A/ro unknown
- 1971-10-05 RO RO7100073335A patent/RO62357A/ro unknown
- 1971-10-05 AT AT734873A patent/AT318565B/de not_active IP Right Cessation
- 1971-10-05 HU HUBO1319A patent/HU163226B/hu unknown
- 1971-10-05 CS CS4618A patent/CS172950B2/cs unknown
- 1971-10-05 RO RO73334A patent/RO62356A/ro unknown
- 1971-10-05 AT AT859371A patent/AT318561B/de not_active IP Right Cessation
- 1971-10-05 RO RO68372A patent/RO61540A/ro unknown
- 1971-10-05 AT AT735473A patent/AT318571B/de not_active IP Right Cessation
- 1971-10-05 AT AT735573A patent/AT318572B/de not_active IP Right Cessation
-
1972
- 1972-02-17 ES ES399874A patent/ES399874A1/es not_active Expired
- 1972-02-17 ES ES399872A patent/ES399872A1/es not_active Expired
- 1972-02-17 ES ES399871A patent/ES399871A1/es not_active Expired
- 1972-02-17 ES ES399870A patent/ES399870A1/es not_active Expired
- 1972-02-17 ES ES399868A patent/ES399868A1/es not_active Expired
- 1972-02-17 ES ES399869A patent/ES399869A1/es not_active Expired
- 1972-02-17 ES ES399873A patent/ES399873A1/es not_active Expired
-
1973
- 1973-02-28 SU SU731888527A patent/SU677649A3/ru active
-
1975
- 1975-04-03 CH CH414475A patent/CH564515A5/xx not_active IP Right Cessation
-
1976
- 1976-12-06 CH CH1430971A patent/CH587227A5/xx not_active IP Right Cessation
-
1979
- 1979-02-02 YU YU236/79A patent/YU35577B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6354321A (ja) | 血糖降下剤 | |
| RU2002131885A (ru) | Антраниламиды и их применение в качестве лекарственных средств | |
| PL93591B1 (pl) | ||
| FI74703B (fi) | Foerfarande foer framstaellning av terapeutiskt verksamma 3,1-bensoxazin-2-oner. | |
| US3944549A (en) | Amino derivatives of 1,4-benzodioxan | |
| PL84267B1 (pl) | ||
| SU812175A3 (ru) | Способ получени замещенных 2- фЕНилиМиНО-иМидАзОлидиНОВ или иХСОлЕй | |
| DE2360545A1 (de) | Neue trialkoxyaroyldiamine | |
| IL39147A (en) | Amino alcohols derived from ortho trans-hydroxycinnamic acids,their esters and their amides,preparation thereof and pharmaceutical compositions containing them | |
| IL25510A (en) | Phenoxypropylamines,their preparation and use | |
| US3959283A (en) | Amino-derivatives of 1,4-benzodioxan | |
| US3287469A (en) | Naphthyl-and indanylimidazolines | |
| ES378520A1 (es) | Procedimiento para la preparacion de nuevos esteres basi- cos. | |
| NO138561B (no) | Analogifremgangsmaate til fremstilling av terapeutisk virksomme cykloalkylfenoksykarboksylsyrederivater | |
| US4117131A (en) | Method of inhibiting gastric acid secretions with 2-(4-pyrimidinyl)thioacetamides | |
| IL29445A (en) | Phenoxyisoalkyl imidazolines and their preparation | |
| PL77004B1 (pl) | ||
| US3819617A (en) | Pyrazolyl-phenylalkylamino-ketones | |
| US3350407A (en) | Sulfur containing pyrazole derivatives | |
| US4107437A (en) | 2,3-Dihydrobenzofurans | |
| PL90714B1 (pl) | ||
| HU178272B (en) | Process for preparing new piperazino-methane-imino derivatives | |
| US3597435A (en) | Substituted phenoxymethyldioxolanes | |
| JP5107497B2 (ja) | 鎮咳活性を有する1,3−ジオキソラン | |
| US4036972A (en) | 2-(N-thienylmethyl-phenylamino)-imidazolines-(2) and salts thereof |